Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1887 • ACR Convergence 2023
Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients
Dario Mazza¹, Siba Raychaudhuri², Yasser Abdelhafez¹ and Abhijit Chaudhari³, ¹University of California Davis, Sacramento, CA, ²UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ³UC Davis School of Medicine, Sacramento, CA
Background/Purpose: To evaluate the ability of total-body PET (TB-PET) biomarkers to quantify enthesitis in Psoriatic (PsA) and Rheumatoid Arthritis (RA). We hypothesize that objective characterization…
Abstract Number: 2238 • ACR Convergence 2023
Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Enrique Soriano², Jan Dutz³, Carlo Selmi⁴, Emmanouil Rampakakis⁵, Natalie shiff⁶, Francois Nantel⁷, Frederic Lavie⁸ and Laura Coates⁹, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Department of Dermatology and Skin Science, Vancouver General Hospital, Vancouver, BC, Canada, ⁴Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) has been associated with an increased risk of cardiovascular (CV) disease, likely due to accelerated atherosclerosis secondary to chronic inflammation.1 As…
Abstract Number: 2254 • ACR Convergence 2023
The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng², Ruru Guo³ and Bharat Kumar⁴, ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²The Wright Center for Graduate Medical Education, Scranton, PA, ³Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ⁴University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis…
Abstract Number: 0342 • ACR Convergence 2023
Assessing the Known-group Validity of the IDEOM MSK-Q Using Data from the National Psoriasis Foundation Annual Survey
Lourdes Perez-Chada¹, George Gondo², Joseph F. Merola³ and Alice B. Gottlieb⁴, ¹Brigham and Women's Hospital, Boston, MA, ²National Psoriasis Foundation, Alexandria, VA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: The IDEOM MSK-Q aims to assess MSK symptoms in individuals with psoriatic disease. It consists of 3 subscales: Intensity of MSK Symptom (3 items),…
Abstract Number: 0494 • ACR Convergence 2023
Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque
Dionicio A. Galarza-Delgado¹, Iris Colunga¹, José Ramón Azpiri-López¹, Valeria Gonzalez-Gonzalez², Rosa Arvizu-Rivera³, Victor Beltran⁴, Angel Arias Peralta⁵ and Jesus Alberto Cardenas-De la Garza⁶, ¹Hospital Universitario UANL, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Triglyceride Glucose Index (TyG) is a surrogate marker positively correlated with atherosclerotic burden in patients with psoriatic arthritis (PsA). Atherosclerotic index of plasma (AIP)…
Abstract Number: 0511 • ACR Convergence 2023
Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
Philip J. Mease¹, Denis Poddubnyy², Ana-Maria Orbai³, Richard B. Warren⁴, Carmen Fleurinck⁵, Rajan Bajracharya⁶, Barbara Ink⁶, Ute Massow⁷, Vishvesh Shende⁶, Julie Shepherd-Smith⁶, Luke Peterson⁸, Katy White⁶, Robert BM Landewé⁹ and Lianne Gensler¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Monheim am Rhein, Germany, ⁸UCB Pharma, Raleigh, NC, ⁹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ¹⁰University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A. A previous analysis of pooled safety data from the…
Abstract Number: 1041 • ACR Convergence 2023
Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging
Mikkel Østergaard¹, Mikael Boesen², Walter P. Maksymowych³, Robert Lambert⁴, Guillermo Valenzuela⁵, Michael Bubb⁶, Olga Kubassova⁷, Jyotsna Reddy⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Zhenwei Zhou⁸ and Philip J. Mease¹², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶University of Florida, Gainesville, FL, ⁷Image Analysis Group, Philadelphia, PA, ⁸Amgen, Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Halton Hills, ON, Canada, ¹⁰Amgen, Inc., Lexington, KY, ¹¹Amgen, Inc., Agoura Hills, CA, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Apremilast is an oral phosphodiesterase 4 inhibitor with a unique immunomodulatory mechanism of action and is approved for the treatment of psoriatic arthritis (PsA).…
Abstract Number: 1416 • ACR Convergence 2023
Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis
Ulf Lindström¹, Daniela Di Giuseppe², Sofia Exarchou³, Gerd-Marie Alenius⁴, Tor Olofsson⁵, Eva Klingberg¹, Lennart Jacobsson⁶, Johan Askling² and Johan Karlsson Wallman⁵, ¹University of Gothenburg, Gothenburg, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Lund University, Åkarp, Sweden, ⁴Umeå University, Umeå, Sweden, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶University of Gothenburg, Malmö, Sweden
Background/Purpose: In many countries, methotrexate (MTX) monotherapy is the first-line disease-modifying anti-rheumatic drug (DMARD) therapy for psoriatic arthritis (PsA), despite that its efficacy in PsA…
Abstract Number: 1433 • ACR Convergence 2023
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Joseph Merola¹, Philip J. Mease², Atul Deodhar³, Barbara Ink⁴, Carmen Fleurinck⁵, Rajan Bajracharya⁴, Jason Coarse⁶ and Laura Coates⁷, ¹Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…
Abstract Number: 1687 • ACR Convergence 2023
Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials
Lihi Eder¹, Sivakami Mylvaganam², Jordi Pardo Pardo³, Jennifer Petkovic⁴, Vibeke Strand⁵, Philip J. Mease⁶ and Keith Colaco⁷, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Department of Biochemistry, University of Toronto, Toronto, ON, Canada, ³Cochrane Musculoskeletal, University of Ottawa, Ottawa, ON, Canada, ⁴Cochrane Equity Methods Group, University of Ottawa, Ottawa, ON, Canada, ⁵Stanford University, Portola Valley, CA, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁷Women’s College Research Institute / Department of Health and Society, University of Toronto, Toronto, ON, Canada
Background/Purpose: Limited information exists on participation and study outcomes by sex in randomized controlled trials (RCTs) among patients with psoriatic arthritis (PsA). Through a systematic…
Abstract Number: 1891 • ACR Convergence 2023
Effect of Apremilast on Disease Interception in Patients with Psoriasis at Increased Risk of Developing PsA – Results of the Prospective Interventional Epos Trial
David Simon¹, Ioanna Minopoulou¹, Sara Bayat¹, Koray Tascilar¹, Melek Yalcin Mutlu¹, Filippo Fagni¹, Georg Schett² and Arnd Kleyer³, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ³Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Entheseal bone changes occur in a substantial proportion of psoriasis patients [1] and are associated with an increased risk of developing psoriatic arthritis (PsA)…
Abstract Number: 2239 • ACR Convergence 2023
Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials
Arthur Kavanaugh¹, Kristi Mizelle², Oliver FitzGerald³, Enrique Soriano⁴, Peter Nash⁵, Sandra Ciecinski⁶, Limei Zhou⁶, Arathi Setty⁶ and Laure Gossec⁷, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Tidewater Physicians Multispecialty Group, Newport News, VA, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Brisbane, Australia, ⁶AbbVie, Inc., North Chicago, IL, ⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: A main goal of therapy for patients (pts) with PsA is to achieve and maintain the lowest possible level of disease activity across domains.1…
Abstract Number: 2256 • ACR Convergence 2023
The Impact of Clinical Trial Metrics in Psoriatic Arthritis
Maxine Yarnall and Kara Murray, Spherix Global Insights, Exton, PA
Background/Purpose: Rheumatologists have access to a plethora of advanced biologic and small molecule agents for the treatment of psoriatic arthritis (PsA). Prior to FDA approval,…
Abstract Number: 072 • 2023 Pediatric Rheumatology Symposium
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Laura Nedorezov, Tracy Ting and Patricia Vega-Fernandez, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…
Abstract Number: L02 • ACR Convergence 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Christopher Ritchlin¹, Laura Coates², Iain McInnes³, Philip J. Mease⁴, Joseph Merola⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Laure Gossec⁸, Alice Gottlieb⁹, Diamant Thaci¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Vish Shende¹¹, Jason Coarse¹² and Robert Landewé¹³, ¹University of Rochester Medical Center, Rochester, NY, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ³College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, ¹³Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].